Artificially Intelligent Labskin
Labskin, a wholly-owned subsidiary of Integumen plc., (AIM:SKIN) today announces that it has entered into a partnership with RinoLab.
RinoLab will provide Labskin clients with access to an AI machine learning platform which accelerates development of cosmetics, skincare, woundcare, personal hygiene and pharmaceutical topical drug delivery products, and does not require animal testing.
Artificially Intelligent Labskin Service
Labskin AI is an AI-based laboratory-grown human-skin testing platform. It uses clinical trial test protocols and datasets, eliminating the need for animal testing completely for the development of all skin care products. The AI platform and physical Labskin laboratories offer clients an online end to end skin care product validation system, tested on laboratory-grown human skin.
Labskin is Expanding
Due to the recent increase in demand for Labskin services, additional laboratory development support services are being provided through an agreement signed with Sheffield Hallam University, UK.
Gerard Brandon (CEO of Integumen plc and Director of Innovenn Ltd) commented:
“We are delighted to announce this collaboration of technologies and work with the skills and expertise of the RinoLab Team on the Labskin AI platform. Partnering with clinical research organisations raises the bar for manufacturers of skin care products in quality control for consumer product information file (PIF) verification. Sheffield Hallam University has worked with Innovenn for many years in multiple Labskin development projects and extends the reach of our development services for our clients. Labskin has successfully moved from selling Labskin equipment supplies to being a fully fledged service provider during H2 2018, increasing our orders by 350% over H1. I believe that Labskin AI is now the ultimate go-to-market service for skin care product development, comprising formulation efficacy, testing and certification for EU and US consumer product launches.”